Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Summary

This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of HB0017 Injection in the treatment of moderate to severe plaque psoriasis in adults.

Timeline

Start

2024-03-01

Primary completion

2024-08

Completion

2025-12

Drugs

Indications